This may seem like a simple question, but when you consider the factors that impact data quality, it is quite complex. Not unlike other businesses, pharma relies on a rich flow of data for making and assessing strategic decisions. For pharma, data comes from many different sources. The ability to capture patient data from multiple disparate sources, such as SP and HUB data, and integrate it...
Read More
Imagine that your company is preparing to launch a new branded drug with distinct advantages in efficacy and side-effect profile. You are challenged by a crowded market dominated by generics. Ninety-six percent of the market share is shared across multiple generics; three other branded products compete for the remaining 4%. The market value is high, so dominating the branded competitors is not only a significant...
Read More
When selecting a partner for the de-identification, integration, and management of patient data — while securing patient privacy — it's important to ensure the use of the right technologies and processes. It's equally as important to weigh the value of all the additional benefits (service, flexibility, etc.) a potential partner provides. Providing best-in-class de-identification and matching capabilities, MSA offers the most credentialed, most configurable, and most trusted data management solutions,...
Read More
Over the past decade, the distribution model for medication delivery has evolved from retail pharmacies and mail order to Specialty Pharmacies (SP), 340B Contract Pharmacies, and Rare Disease Pharmacies. In addition, large health systems are continuing the trend of market consolidation by purchasing physician practices, smaller regional hospitals, long-term care facilities and other ancillary healthcare services. These health systems are using their size and influence...
Read More
Pharma is facing the many challenges of COVID-19 head-on. Leading organizations are taking full advantage of today’s sophisticated analytic tools, including state-of-the-art anonymization technologies that seamlessly link patient data across multiple sources, to monitor the impact of COVID-19 on treatments in new ways. Since the COVID-19 pandemic began, the industry has been primarily focused on understanding the journey of severely ill, older adults requiring hospitalization. More...
Read More
MSA’s Healthcare Data Management experts provide solutions that empower pharma to better understand the impact of COVID-19 on the diabetes patient journey by linking clinical lab results, prescriptions, EMR, and medical claims data – all while protecting patient privacy. MSA, provider of the industry’s most credentialed, configurable, and trusted de-identification and data management solutions, accurately anonymizes and seamlessly links disparate data from one or multiple...
Read More
A close examination of the COVID-19 patient journey will result in a better understanding of the impact of the virus on at-risk diabetes patients. Segmenting positive and negative COVID-19 patients provides a real world comparison of anonymized patient cohorts’ A1C, fasting blood sugars, and glucose levels. Linked with prescribed medications, this data will identify the impact of COVID-19 on the patients’ prescribed drug therapy. The...
Read More
Patient-level data matching, a fundamental and critical success factor for the longitudinal alignment of anonymized health information, can be a daunting challenge given the complexity, sensitivity, volume, and heterogeneity of patient healthcare data, as well as the use of primitive technologies. A comprehensive picture of the anonymized patient requires accurate matching of individual patients to their health records across settings, however, patient matching rates vary widely. Matching records to the correct anonymized...
Read More